PE20161153A1 - Insulina de accion prolongada y uso de la misma - Google Patents
Insulina de accion prolongada y uso de la mismaInfo
- Publication number
- PE20161153A1 PE20161153A1 PE2016001252A PE2016001252A PE20161153A1 PE 20161153 A1 PE20161153 A1 PE 20161153A1 PE 2016001252 A PE2016001252 A PE 2016001252A PE 2016001252 A PE2016001252 A PE 2016001252A PE 20161153 A1 PE20161153 A1 PE 20161153A1
- Authority
- PE
- Peru
- Prior art keywords
- alanine
- insulin
- formula
- insulin analog
- long
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se refiere a un analogo de insulina que comprende una cadena A de formula 1 de la SEQ ID NO: 37 donde Xaa1 es glicina o alanina, Xaa2 es isoleucina o alanina, Xaa3 es tirosina, acido glutamico o asparagina y Xaa4 es tirosina o alanina; y una cadena B de formula 2 de la SEQ ID NO: 38 donde Xaa5 y Xaa6 son glicina o alanina, Xaa7 y Xaa8 son fenilalanina o alanina. Tambien se refiere a un conjugado de formula X-La-F, donde X es el analogo de insulina descrito anteriormente; L es un ligando tal como un peptido, un polimero, entre otros; a es 0 o un numero natural, F es un material capaz de aumentar la vida media in vivo del analogo de insulina tal como una region Fc de IgG. Dicho analogo de insulina presenta una afinidad reducida de la union al receptor de insulina con el proposito de aumentar la vida media en sangre de la insulina, siendo util como insulina de accion prolongada
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140006938 | 2014-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161153A1 true PE20161153A1 (es) | 2016-10-27 |
Family
ID=53543214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001252A PE20161153A1 (es) | 2014-01-20 | 2015-01-20 | Insulina de accion prolongada y uso de la misma |
Country Status (22)
Country | Link |
---|---|
US (1) | US10253082B2 (es) |
EP (1) | EP3098235A4 (es) |
JP (1) | JP2017505141A (es) |
KR (1) | KR102406654B1 (es) |
CN (2) | CN116987172A (es) |
AU (1) | AU2015206890B2 (es) |
BR (1) | BR112016016578A2 (es) |
CA (1) | CA2937168A1 (es) |
CL (1) | CL2016001844A1 (es) |
CR (1) | CR20160376A (es) |
DO (1) | DOP2016000176A (es) |
EA (1) | EA201691374A1 (es) |
EC (1) | ECSP16068524A (es) |
IL (1) | IL246782B (es) |
MA (3) | MA46146A1 (es) |
MX (1) | MX369656B (es) |
MY (1) | MY186251A (es) |
PE (1) | PE20161153A1 (es) |
PH (1) | PH12016501414B1 (es) |
SG (1) | SG11201605680PA (es) |
WO (1) | WO2015108398A1 (es) |
ZA (1) | ZA201605626B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016009465A (es) | 2014-01-20 | 2016-12-02 | Cleave Biosciences Inc | Pirimidinas fusionadas como inhibidores del complejo p97. |
EA036714B1 (ru) | 2014-11-21 | 2020-12-10 | Мерк Шарп И Доум Корп. | Частичные агонисты инсулинового рецептора |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
WO2017052305A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Method of insulin production |
TWI774694B (zh) * | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
CN110545849A (zh) | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
CA3054899A1 (en) * | 2017-03-23 | 2018-09-27 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
CN111406073A (zh) * | 2017-09-29 | 2020-07-10 | 韩美药品株式会社 | 具有提高功效的持久性蛋白质缀合物 |
KR102666154B1 (ko) * | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
KR102646845B1 (ko) | 2018-08-08 | 2024-03-14 | 주식회사 대웅제약 | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 |
TW202039438A (zh) | 2018-12-11 | 2020-11-01 | 法商賽諾菲公司 | 胰島素接合物 |
JP2022542301A (ja) * | 2019-07-31 | 2022-09-30 | イーライ リリー アンド カンパニー | リラキシン類似体およびその使用方法 |
KR102545250B1 (ko) * | 2020-03-31 | 2023-06-21 | 한미약품 주식회사 | 신규한 면역 활성 인터루킨 2 아날로그 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
US5422339A (en) * | 1991-03-19 | 1995-06-06 | Joslin Diabetes Center, Inc. | Peptides having insulin autoantibody but not insulin receptor binding capacity |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
IL143866A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
DK1648933T3 (da) | 2003-07-25 | 2009-09-07 | Conjuchem Biotechnologies Inc | Langvarige insulinderivater og fremgangsm der |
PT2256134E (pt) | 2003-11-13 | 2014-03-05 | Hanmi Science Co Ltd | Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo |
JP5366546B2 (ja) | 2005-08-16 | 2013-12-11 | ノボ・ノルデイスク・エー/エス | 成熟インスリンポリペプチドの作製方法 |
EP2049149B1 (en) * | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
WO2008049711A1 (en) * | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
US7790677B2 (en) | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
EP2017288A1 (en) | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
JP5688969B2 (ja) * | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー/エス | プロテアーゼに対して安定しているペグ化インスリンアナログ |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
US9150633B2 (en) | 2007-08-15 | 2015-10-06 | Novo Nordisk A/S | Insulin analogues with an acyl and alkylene glycol moiety |
JP5241849B2 (ja) | 2007-11-16 | 2013-07-17 | ノボ・ノルデイスク・エー/エス | インスリン及びインスリン分泌性ペプチドを含む薬学的組成物 |
DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
KR20100111683A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
WO2009112583A2 (en) * | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
EP2376520B1 (en) | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
MX2011010151A (es) | 2009-03-27 | 2011-12-14 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
US20120184488A1 (en) * | 2009-09-01 | 2012-07-19 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
KR101058209B1 (ko) | 2009-12-30 | 2011-08-22 | 전자부품연구원 | Ofdm 방식의 디지털 방송 시스템의 빠른 동기 방법 |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101324828B1 (ko) | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
US8940860B2 (en) * | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
AU2011282988A1 (en) | 2010-07-28 | 2013-01-31 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
EA201390796A1 (ru) | 2011-01-20 | 2014-07-30 | Зилэнд Фарма А/С | Применение ацилированного аналога глюкагона |
CN103635602B (zh) | 2011-03-02 | 2016-08-31 | 欧瑞康表面解决方案股份公司,普费菲孔 | 用于在润滑条件下通过摩擦应用改进磨损和摩擦性能的用含金属碳层涂布的滑动组件 |
CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
RU2578641C2 (ru) | 2011-05-03 | 2016-03-27 | Тейджин Арамид Б.В. | Пуленепробиваемая панель |
BR112013030933A2 (pt) | 2011-06-02 | 2018-04-24 | Prolor Biotech Inc | agonistas do receptor de glp-1/glucágon de ação prolongada |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
PE20140765A1 (es) | 2011-06-10 | 2014-06-14 | Hanmi Science Co Ltd | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos |
ES2710356T3 (es) | 2011-06-17 | 2019-04-24 | Hanmi Science Co Ltd | Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
WO2013089463A1 (en) | 2011-12-16 | 2013-06-20 | Lg Innotek Co., Ltd. | Method for deposition of silicon carbide and silicon carbide epitaxial wafer |
JP2015507916A (ja) | 2012-01-20 | 2015-03-16 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | グルタミン酸安定化インスリン類似体 |
KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
PH12018501454A1 (en) | 2012-11-06 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment |
PE20151409A1 (es) | 2013-02-26 | 2015-10-07 | Hanmi Pharm Ind Co Ltd | Analogo de insulina novedoso y su uso |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
KR101676542B1 (ko) | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
-
2015
- 2015-01-20 CN CN202311024383.1A patent/CN116987172A/zh active Pending
- 2015-01-20 MA MA46146A patent/MA46146A1/fr unknown
- 2015-01-20 CA CA2937168A patent/CA2937168A1/en not_active Abandoned
- 2015-01-20 US US15/113,027 patent/US10253082B2/en active Active
- 2015-01-20 MX MX2016009434A patent/MX369656B/es active IP Right Grant
- 2015-01-20 KR KR1020150009433A patent/KR102406654B1/ko active IP Right Grant
- 2015-01-20 EA EA201691374A patent/EA201691374A1/ru unknown
- 2015-01-20 EP EP15737856.3A patent/EP3098235A4/en not_active Withdrawn
- 2015-01-20 MY MYPI2016702501A patent/MY186251A/en unknown
- 2015-01-20 AU AU2015206890A patent/AU2015206890B2/en not_active Ceased
- 2015-01-20 JP JP2016564933A patent/JP2017505141A/ja active Pending
- 2015-01-20 BR BR112016016578A patent/BR112016016578A2/pt not_active Application Discontinuation
- 2015-01-20 SG SG11201605680PA patent/SG11201605680PA/en unknown
- 2015-01-20 MA MA39301A patent/MA39301A1/fr unknown
- 2015-01-20 CR CR20160376A patent/CR20160376A/es unknown
- 2015-01-20 CN CN201580004573.4A patent/CN105916877A/zh active Pending
- 2015-01-20 WO PCT/KR2015/000576 patent/WO2015108398A1/ko active Application Filing
- 2015-01-20 MA MA43289A patent/MA43289B1/fr unknown
- 2015-01-20 PE PE2016001252A patent/PE20161153A1/es unknown
-
2016
- 2016-07-14 DO DO2016000176A patent/DOP2016000176A/es unknown
- 2016-07-14 IL IL246782A patent/IL246782B/en not_active IP Right Cessation
- 2016-07-18 PH PH12016501414A patent/PH12016501414B1/en unknown
- 2016-07-20 CL CL2016001844A patent/CL2016001844A1/es unknown
- 2016-08-15 ZA ZA2016/05626A patent/ZA201605626B/en unknown
- 2016-08-19 EC ECIEPI201668524A patent/ECSP16068524A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016009434A (es) | 2017-01-18 |
MA46146A1 (fr) | 2020-12-31 |
CN105916877A (zh) | 2016-08-31 |
CL2016001844A1 (es) | 2017-01-06 |
IL246782B (en) | 2020-01-30 |
DOP2016000176A (es) | 2017-02-15 |
MA39301A1 (fr) | 2018-01-31 |
EP3098235A1 (en) | 2016-11-30 |
AU2015206890A1 (en) | 2016-08-04 |
ZA201605626B (en) | 2017-11-29 |
US10253082B2 (en) | 2019-04-09 |
CA2937168A1 (en) | 2015-07-23 |
PH12016501414A1 (en) | 2016-09-14 |
ECSP16068524A (es) | 2018-11-30 |
EA201691374A1 (ru) | 2016-12-30 |
IL246782A0 (en) | 2016-08-31 |
US20170101455A1 (en) | 2017-04-13 |
CR20160376A (es) | 2016-10-07 |
EP3098235A4 (en) | 2017-10-18 |
MX369656B (es) | 2019-11-15 |
KR20150087130A (ko) | 2015-07-29 |
PH12016501414B1 (en) | 2016-09-14 |
BR112016016578A2 (pt) | 2017-10-03 |
CN116987172A (zh) | 2023-11-03 |
SG11201605680PA (en) | 2016-09-29 |
KR102406654B1 (ko) | 2022-06-10 |
JP2017505141A (ja) | 2017-02-16 |
MA43289B1 (fr) | 2019-12-31 |
MY186251A (en) | 2021-06-30 |
AU2015206890B2 (en) | 2019-05-23 |
WO2015108398A1 (ko) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161153A1 (es) | Insulina de accion prolongada y uso de la misma | |
CL2018000124A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer | |
PE20171515A1 (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer | |
AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
HRP20211561T1 (hr) | Modulacija aktivnosti komplementa | |
PE20060713A1 (es) | Polipeptidos moduladores del peptido 1 similar al glucagon humano | |
PE20181316A1 (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer | |
PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
EP3712165A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
PE20130523A1 (es) | Nuevos peptidos y metodos para su preparacion y uso | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
RU2019124678A (ru) | Слитый белок pd1-41bbl и способы его применения | |
CL2020000817A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional solicitud 201902093) | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
PE20180253A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer | |
CL2019003425A1 (es) | Nuevos péptidos (seq id n°42), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
MX364911B (es) | Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. | |
PH12015501815B1 (en) | Site-specific insulin conjugate | |
EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии | |
MX2022000251A (es) | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. | |
WO2011048503A3 (en) | Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof | |
AR111341A1 (es) | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo | |
WO2015150492A3 (en) | An isolated donor mhc-derived peptide and uses thereof | |
WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |